|Treatments:||Radiation||Hospital:||Princess Alexandra Hospital|
Patients: This phase II study involved 234 patients with malignant melanoma. The median age was 57 years, ranging from 20 to 89. The majority (73%) of patients were men.
Treatment: After surgery, patients received radiation therapy to the nodal basin.
Toxicity: The most common grade Grade 3 toxicity was lymphoedema, occurring in 19% of patients with inguinal/iliac disease site, and 9% of patients with axilla disease site. Other Grade 3 / 4 toxicities were subcutaneous changes, nerve/spinal damage, skin changes, bone/joint changes, and mucositis.
Results: The overall survival was 36% at 5 years. The progression free survival was 27% at 5 years. Median survival times were not reported.
Correspondence: Dr. Bryan H. Burmeister